Results 131 to 140 of about 143,744 (251)

1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma. [PDF]

BJUI Compass
Sharma RK, Solaiyappan M, Feinaj A, Brönimann S, Singla N, Bhujwalla ZM, Ged Y.   +6 more
europepmc   +1 more source

Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma. [PDF]

Front Pharmacol
Zhu H, Lin Q, Yu Z, Huang X.
europepmc   +1 more source

Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series. [PDF]

Case Rep Urol
Tessa Djambong R, Follah Feudjio BL, Rysselinck S, Seront E, Niegisch G, Neppl C, Müller A.   +6 more
europepmc   +1 more source

Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters. [PDF]

J Clin Invest
Haddad G, Guo J, Xi Y, Albayrak E, Huseni M, Hamidi H, Banchereau R, Kadel E, Dubey S, Carter C, Kapur P, Brugarolas J, Pedrosa I.   +12 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Epithelial-Mesenchymal Transition Markers in Clear Cell Renal Cell Carcinoma: Expression Patterns and Prognostic Significance. [PDF]

J Pers Med
Smoljo L, Mateljak T, Racetin A, Todorović P, Komić J, Komić L, Đolonga P, Grubišić DA, Kostić S, Vukojević K, Kelam N.   +10 more
europepmc   +1 more source

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma

BMEMat, EarlyView.
This article introduces a biomimetic Mn‐doped polydopamine nanoplatform (HAMM NPs) coated with cancer cell membranes. It enables targeted hepatocellular carcinoma theranostics via T1/T2 dual‐mode magnetic resonance imaging and tumor microenvironment‐triggered sonodynamic therapy/chemodynamic therapy, achieving potent antitumor efficacy in subcutaneous ...
Jiayin Lin, Wenbo Chen, Xiuqi Hou, Kai Wang, Fan Liu, Ruling Zhang, Zhong Cao, Jian Zheng   +7 more
wiley   +1 more source

DaRenCa risk score: A prognostic model for recurrence in clear cell renal cell carcinoma. [PDF]

BJUI Compass
Hedegaard P, Petersson RD, Al-Husseinawi H, Heeno E, Lunetcas M, Tolouee S, Bak R, Pedersen OB, Vásquez JL, Lund L, Thomsen FF.   +10 more
europepmc   +1 more source